jeudi 18 juin 2020

Onco Actu du 18 juin 2020

The new test, known as PrOTYPE (Predictor of high-grade serous Ovarian carcinoma molecular subTYPE), is specifically designed to analyze and classify high-grade serous ovarian cancer, the most common and lethal form of ovarian cancer.

The technique uses personalised genetic testing of a patient’s tumour to search blood samples for hundreds of different genetic mutations in circulating tumour DNA (ctDNA); DNA released by cancer cells into the bloodstream.

The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, according to a study published today in the New England Journal of Medicine.
Cardioprotective therapies, especially statins and antiplatelet agents, may be underutilized in patients with a prior or current history of cancer compared with patients without cancer and comparable cardiovascular risk factors, according to a study published June 16 in JACC: CardioOncology. 

ARID1A mutations and CXCL13 expression in baseline tumor tissues associated with improved survival, may improve patient selection.

FDA approves pembrolizumab for adults and children with TMB-H solid tumors [FDA] 
Efficacy was investigated in a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic TMB-H solid tumors enrolled in a multicenter, non-randomized, open-label trial, KEYNOTE-158 (NCT02628067). 

FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type [Merck] 
KEYTRUDA Is the First Checkpoint Inhibitor Approved for These Patients with TMB-H Solid Tumors.

FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab) [Foundation Medicine] 
FoundationOne CDx is the first and only FDA-approved companion diagnostic to measure TMB and help identify patients who may be appropriate for treatment with KEYTRUDA, regardless of solid tumor type.

With latest Keytruda approval, Merck beats Bristol Myers to a new immunotherapy target [Biopharma Dive] 
The decision marks the second so-called tissue agnostic approval for Keytruda, which made history in 2017 when the Food and Drug Administration cleared it for patients whose tumors have one of two genetic problems — microsatellite instability-high or mismatch repair deficiency. 

Merck's Keytruda nabs 2nd biomarker-driven FDA nod, regardless of tumor type [Fierce Pharma] 
Among the 30 patients who responded, half had ongoing responses of two years or longer. The median duration of response had not been reached after a median follow-up of 11.1 months.

Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda [EndPoints] 
The OK for unresectable or metastatic TMB-high solid tumors — defined as 10 mutations per megabase or more — is the second biomarker-based indication for Keytruda that covers tumors that fit the bill regardless of where in the body they originate.

Researchers from the Josep Carreras Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution.

Scientists at Memorial Sloan Kettering have genetically engineered immune cells to find and kill cells that contribute to diseases caused by senescence, a tissue-damaging inflammatory process. Studies in mice show that these engineered cells can kill their targets without causing undue toxicity.

Focus on Targeted Thorium Conjugate (TTC) platform, the company’s proprietary targeted alpha therapies program / Synergistic effects of investigational PSMA-TTC in combination with androgen receptor inhibitor darolutamide in preclinical prostate cancer.